Particle.news

Download on the App Store

Plasma-Activated Medium Shows Promise in Treating Rare Synovial Sarcoma

Osaka Metropolitan University researchers demonstrate selective tumor suppression and minimal side effects in preclinical studies of plasma-activated medium therapy.

Image

Overview

  • Plasma-activated medium (PAM) reduced synovial sarcoma tumor volume by 54% and tumor weight by 41% in mouse models after four weeks of daily injections.
  • In vitro studies showed only 21% of synovial sarcoma cells survived after exposure to PAM prepared with five minutes of plasma irradiation.
  • The treatment selectively induces apoptosis in cancer cells through reactive oxygen and nitrogen species, sparing healthy cells and minimizing systemic toxicity.
  • Mice treated with PAM exhibited no observable side effects, such as weight loss or appetite changes, underscoring its safety profile.
  • Researchers aim to refine plasma generation parameters and explore combination therapies to advance PAM toward clinical trials for this aggressive cancer.